Every FDA Oncology Approval Notice in October 2026

October was not a month of new molecules. All seven oncology approval notices the FDA posted in October 2026 went to medicines already on the market, and each moved a drug into a new position, whether earlier in treatment, into maintenance, after surgery, or into a different biomarker-defined group. [1] These changes are harder to track than a new approval, because the drug name stays the same while the patients it competes for change.

Updated November 3, 2026

Pirtobrutinib enters a crowded first-line CLL/SLL market

Pirtobrutinib's October 2 approval covers adults with previously untreated CLL/SLL and no known 17p deletion. BRUIN CLL-313 enrolled 282 patients and compared pirtobrutinib with bendamustine plus rituximab. The progression-free survival hazard ratio was 0.20; median PFS was not estimable with pirtobrutinib versus 33.5 months with the comparator. Overall-survival data were immature. [2]

Approved competitors in this setting include zanubrutinib (Brukinsa) and acalabrutinib (Calquence) plus venetoclax (Venclexta). Both have randomized evidence in previously untreated CLL, including populations without 17p deletion. [3] [4] Venetoclax plus obinutuzumab (Gazyva) is another approved first-line regimen. [5] Incumbent targeted regimens therefore face a new first-line competitor whose pivotal evidence establishes an advantage over chemoimmunotherapy, leaving its relative position against those targeted options unresolved.

Tucatinib competes at the maintenance transition

The same competition for an earlier treatment decision extends to breast-cancer maintenance, where tucatinib's October 7 approval adds it to trastuzumab and pertuzumab after induction for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. HER2CLIMB-05 enrolled 654 adults without progression after trastuzumab, pertuzumab, and a taxane. Median PFS was 24.9 months with tucatinib versus 16.3 months with placebo, each on the antibody backbone; overall-survival data were immature. [6]

For the HR-positive subset, an approved competing maintenance regimen is palbociclib (Ibrance) plus trastuzumab, with or without pertuzumab, and endocrine therapy. Its June 2026 approval followed PATINA, which compared that regimen with the same antibody and endocrine backbone without palbociclib. [7] Competition at the maintenance decision now depends on hormone-receptor status, with tucatinib challenging palbociclib in HR-positive disease while also reaching the wider HER2-positive population.

Atezolizumab adds immunotherapy after colon-cancer resection

After resection, the competitive question shifts to preventing recurrence, and the October 8 notice adds atezolizumab with a fluoropyrimidine and oxaliplatin for adjuvant Stage III dMMR colon cancer. Tecentriq eligibility starts at age two; Tecentriq Hybreza starts at age 12 and requires a weight of at least 40 kg. In ATOMIC, atezolizumab plus mFOLFOX6 followed by atezolizumab was compared with mFOLFOX6 alone after complete resection. The disease-free-survival hazard ratio was 0.50, with median DFS not reached in either arm. [8]

Chemotherapy remains the direct comparator, with mFOLFOX6 comprising oxaliplatin, leucovorin, and fluorouracil. Capecitabine (Xeloda), alone or as part of combination chemotherapy, is also approved for adjuvant Stage III colon cancer. [9] The late-stage immunotherapy competitor is dostarlimab in Phase 3 AZUR-2 for untreated, resectable T4N0 or Stage III dMMR/MSI-H colon cancer. That program gives dostarlimab before and after surgery, so it competes earlier in the surgical pathway than atezolizumab's postoperative indication. [10] Atezolizumab gives postoperative immunotherapy an approved position that AZUR-2 could challenge by bringing treatment forward to before surgery.

Anktiva expands into papillary-only bladder cancer

Anktiva changes the eligible population within an existing treatment setting, as its October 14 notice expands its use with BCG to adults with BCG-unresponsive non-muscle invasive bladder cancer containing high-grade papillary-only tumors. The prior indication required carcinoma in situ, with or without papillary tumors. FDA concluded that the earlier efficacy demonstration in CIS-containing disease could be extrapolated to high-grade papillary disease. [11]

A competing late-stage option is TAR-210, the erdafitinib intravesical delivery system, in Phase 3 MoonRISe-3. It enrolls adults with susceptible FGFR alterations and papillary-only high-risk NMIBC (high-grade Ta or any T1, without CIS) after BCG who are ineligible for or refuse radical cystectomy. Eligible groups include BCG-unresponsive, BCG-experienced, and BCG-intolerant patients. The randomized trial compares TAR-210 with investigator's choice of intravesical gemcitabine or mitomycin C. [12] Gemcitabine intravesical system (Inlexzo) is already approved in BCG-unresponsive NMIBC with CIS, with or without papillary tumors. Its approved population overlaps Anktiva's broader indication but does not cover papillary-only disease. [13] Anktiva now has an approved position in papillary-only disease that Inlexzo's current label cannot contest, while TAR-210's potential challenge is confined to FGFR-altered tumors.

Dostarlimab creates an approved rectal-cancer immunotherapy option

Organ preservation also shapes the new position for dostarlimab, which received accelerated approval on October 19 for adults with Stage II/III locally advanced MSI-H or dMMR rectal cancer. AZUR-1 evaluated 154 patients; those achieving a clinical complete response entered non-operative monitoring, while incomplete response, recurrence, or progression could lead to standard treatment. FDA reported a sustained 12-month clinical complete response rate of 47% among 116 patients evaluable by independent central review, alongside supportive investigator-led evidence. [14]

The competing approved chemotherapy option is capecitabine as a component of perioperative chemoradiotherapy for locally advanced rectal cancer. [9] FOLFOX and CAPEOX, built around oxaliplatin with fluorouracil or capecitabine, are established chemotherapy options in Stage II/III treatment pathways. [15] Dostarlimab challenges reliance on chemoradiotherapy in dMMR/MSI-H disease by offering a route to non-operative monitoring, while chemotherapy retains a broader population beyond that biomarker-defined group.

Pembrolizumab narrows the TMB-high eligibility threshold

Biomarker eligibility narrows rather than expands in the pembrolizumab notice, dated October 22 in the index and reporting an October 16 action. FDA converted the TMB-high solid-tumor indication to traditional approval and raised the threshold from at least 10 to at least 13 mutations/Mb. It covers adult and pediatric patients with unresectable or metastatic disease after prior treatment and no satisfactory alternatives. In KEYNOTE-158 patients with TMB of at least 13 mutations/Mb, the objective response rate was 36%; efficacy supporting traditional approval was not confirmed for TMB of 10 to below 13 mutations/Mb. [16]

Approved alternatives depend on an additional qualifying biomarker or tumor type. Dostarlimab has accelerated approval for previously treated dMMR recurrent or advanced solid tumors with no satisfactory alternatives. [17] Nivolumab plus ipilimumab is approved for unresectable or metastatic MSI-H/dMMR colorectal cancer in patients aged 12 or older. [18] The narrower threshold fragments the competitive opportunity across tumor types and biomarkers, because dostarlimab and nivolumab plus ipilimumab remain options only for patients who also meet their distinct labels.

Talazoparib expands PARP competition in hormone-sensitive prostate cancer

Talazoparib combines broader biomarker coverage with an earlier treatment position, as its October 26 approval adds it to enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. In TALAPRO-3, 599 patients received enzalutamide with talazoparib or placebo, alongside ongoing androgen deprivation. The radiographic PFS hazard ratio was 0.48; median rPFS was not reached with talazoparib versus 45.8 months with placebo. Overall-survival data were immature. [19]

The approved PARP-based competitor is niraparib plus abiraterone acetate (Akeega) with prednisone, whose hormone-sensitive indication is limited to BRCA2-mutated disease. [20] Enzalutamide with androgen deprivation is also an approved option in metastatic castration-sensitive prostate cancer, without an HRR-mutation requirement. [21] Talazoparib now challenges Akeega in BRCA2-mutated disease while extending PARP-based competition into other HRR-mutated groups, making the specific gene alteration central to positioning both regimens.

Final Perspective

The next survival updates will shape the case for using October's new regimens in first-line CLL/SLL, HER2-positive breast-cancer maintenance, and hormone-sensitive prostate cancer, where competition with approved targeted regimens is most direct. Overall-survival data were immature at approval in BRUIN CLL-313, HER2CLIMB-05, and TALAPRO-3. Further follow-up will test whether their disease-control advantages translate into longer survival within each trial's comparison.

AZUR-2 will test dostarlimab before and after colon-cancer surgery, while MoonRISe-3 will test TAR-210 against intravesical chemotherapy in FGFR-altered papillary-only bladder cancer. [10] [12] Those readouts could change the alternatives to postoperative atezolizumab and Anktiva, respectively. In dMMR/MSI-H rectal cancer, longer follow-up after dostarlimab will clarify how durable complete responses are during non-operative monitoring, a central question for its role alongside established chemoradiotherapy pathways. [14]

The bladder, rectal, and tumor-agnostic notices make histology and biomarkers central to those future decisions, extending the precision-treatment trend discussed in Maven's 2025 FDA approvals analysis. Papillary-only disease, dMMR/MSI-H status, and the revised TMB threshold define distinct populations even when the drug names recur. As new readouts and label decisions arrive, each will need to resolve which patients gain another option and which remain outside the approved use.

Methodology

The complete list includes every notice dated October 1-31 in the FDA oncology approval-notification index, rechecked November 3. FDA notes that the index does not announce every oncology approval or label update. [1] Notice dates determine inclusion. The October 22 pembrolizumab entry reports an October 16 approval. Each paired-formulation notice counts once.